

# Taher Nassar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5501287/publications.pdf>

Version: 2024-02-01

41  
papers

1,726  
citations

279798

23  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2491  
citing authors

#	ARTICLE	IF	CITATIONS
1	The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure. <i>International Journal of Pharmaceutics</i> , 2022, 617, 121627.	5.2	14
2	Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma. <i>Oncogene</i> , 2021, 40, 334-344.	5.9	1
3	Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. <i>Journal of Controlled Release</i> , 2021, 333, 283-297.	9.9	24
4	Biodistribution and efficacy of the anticancer drug, oxaliplatin palmitate acetate, in mice. <i>International Journal of Pharmaceutics</i> , 2021, 604, 120740.	5.2	3
5	Topical nano-encapsulated cyclosporine formulation for atopic dermatitis treatment. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 24, 102140.	3.3	18
6	Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. <i>Journal of Drug Targeting</i> , 2019, 27, 590-600.	4.4	8
7	Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 133, 214-223.	4.3	11
8	Minit-Livin Conjugated to Targeted Nanoparticles Inhibits Tumorigenicity. <i>Blood</i> , 2018, 132, 4171-4171.	1.4	0
9	Solid nano-in-nanoparticles for potential delivery of siRNA. <i>Journal of Controlled Release</i> , 2017, 257, 144-155.	9.9	23
10	Kinetic characterization and regulation of the human retinaldehyde dehydrogenase 2 enzyme during production of retinoic acid. <i>Biochemical Journal</i> , 2016, 473, 1423-1431.	3.7	21
11	A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9035-9046.	6.4	59
12	Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. <i>Journal of Controlled Release</i> , 2015, 217, 202-210.	9.9	46
13	Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model. <i>Small</i> , 2013, 9, 4221-4236.	10.0	98
14	Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17498-17503.	7.1	119
15	Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model. <i>Current Cancer Drug Targets</i> , 2013, 13, 11-29.	1.6	4
16	High Plasma Levels and Effective Lymphatic Uptake of Docetaxel in an Orally Available Nanotransporter Formulation. <i>Cancer Research</i> , 2011, 71, 3018-3028.	0.9	34
17	Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1015-1021.	2.9	22
18	Neuroprotection by glucagon: role of gluconeogenesis. <i>Journal of Neurosurgery</i> , 2011, 114, 85-91.	1.6	26

#	ARTICLE	IF	CITATIONS
19	Urokinase-type Plasminogen Activator (uPA) Induces Pulmonary Microvascular Endothelial Permeability through Low Density Lipoprotein Receptor-related Protein (LRP)-dependent Activation of Endothelial Nitric-oxide Synthase. <i>Journal of Biological Chemistry</i> , 2011, 286, 23044-23053.	3.4	19
20	A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. <i>Toxicology and Applied Pharmacology</i> , 2010, 246, 83-90.	2.8	82
21	Regulation of Airway Contractility by Plasminogen Activators through N-Methyl-D-Aspartate Receptor $\alpha$ 1. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 43, 703-711.	2.9	24
22	Blood $\alpha$ brain barrier permeability and tPA-mediated neurotoxicity. <i>Neuropharmacology</i> , 2010, 58, 972-980.	4.1	77
23	Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. <i>Journal of Controlled Release</i> , 2009, 133, 77-84.	9.9	95
24	A simple approach discriminating cardio-safe drugs from toxic ones. <i>Bioinformatics</i> , 2009, 3, 389-393.	0.5	3
25	A Novel Nanocapsule Delivery System to Overcome Intestinal Degradation and Drug Transport Limited Absorption of P-glycoprotein Substrate Drugs. <i>Pharmaceutical Research</i> , 2008, 25, 2019-2029.	3.5	34
26	The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 248-259.	4.3	43
27	Neutralizing the neurotoxic effects of exogenous and endogenous tPA. <i>Nature Neuroscience</i> , 2006, 9, 1150-1155.	14.8	69
28	The design and evaluation of a novel targeted drug delivery system using cationic emulsion $\alpha$ antibody conjugates. <i>Journal of Controlled Release</i> , 2005, 108, 418-432.	9.9	33
29	The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation. <i>British Journal of Pharmacology</i> , 2004, 141, 971-978.	5.4	16
30	In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. <i>Blood</i> , 2004, 103, 897-902.	1.4	106
31	Platelet Factor 4 Enhances the Binding of Oxidized Low-density Lipoprotein to Vascular Wall Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 6187-6193.	3.4	116
32	Binding of Urokinase to Low Density Lipoprotein-related Receptor (LRP) Regulates Vascular Smooth Muscle Cell Contraction. <i>Journal of Biological Chemistry</i> , 2002, 277, 40499-40504.	3.4	50
33	Human $\alpha$ -defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor $\alpha$ related protein/ $\alpha$ 2-macroglobulin receptor. <i>Blood</i> , 2002, 100, 4026-4032.	1.4	87
34	Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. <i>Blood</i> , 2002, 99, 3613-3622.	1.4	93
35	Development of 3-nitratomethyl-proxyl (NMP): A novel, bifunctional superoxide dismutase-mimic-nitric oxide-donor. <i>Drug Development Research</i> , 2000, 50, 528-536.	2.9	4
36	Determination of lipoic acid and dihydrolipoic acid in human plasma and urine by high-performance liquid chromatography with fluorimetric detection. <i>Journal of Chromatography A</i> , 2000, 870, 381-388.	3.7	52

#	ARTICLE	IF	CITATIONS
37	Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB Journal, 2000, 14, 1411-1422.	0.5	35
38	Novel Interactions between Urokinase and Its Receptor. Journal of Biological Chemistry, 2000, 275, 24304-24312.	3.4	32
39	Effects of the Superoxide Dismutase-Mimic Compound TEMPOL on Oxidant Stress-Mediated Endothelial Dysfunction. Antioxidants and Redox Signaling, 1999, 1, 221-232.	5.4	21
40	The effect of Eudragit RL-100 on the mechanical and mucoadhesion properties of polycarbophil dosage forms. The results reported here form part of the dissertation projects of M.B. and T.N., completed in partial fulfillment of the requirements of their respective PhD and MSc degrees at the Hebrew University of Jerusalem. The study has been presented in part at the 22nd International Symposium on Controlled Release of Bioactive Materials, Seattle, WA, 1995.1. Journal of Controlled Release, 1997, 45, 57-64.	9.9	22
41	The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. Journal of Controlled Release, 1997, 46, 59-73.	9.9	82